InnoCare Pharma Limited (9969.HK)
HKD 6.1
(0.16%)
HKD 6.1
(0.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.87 Billion CNY | 7.65% |
| 2022 | -7.44 Billion CNY | -59.76% |
| 2021 | -4.66 Billion CNY | -66.67% |
| 2020 | -2.79 Billion CNY | -141.9% |
| 2019 | -1.15 Billion CNY | -36.48% |
| 2018 | -846.94 Million CNY | -950.85% |
| 2017 | 99.54 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -5.51 Billion CNY | 32.18% |
| 2024 Q1 | -8.13 Billion CNY | -18.29% |
| 2023 Q1 | -8.22 Billion CNY | -10.43% |
| 2023 FY | -6.87 Billion CNY | 7.65% |
| 2023 Q3 | -8.2 Billion CNY | -15.95% |
| 2023 Q2 | -7.07 Billion CNY | 13.9% |
| 2023 Q4 | -6.87 Billion CNY | 16.24% |
| 2022 Q4 | -7.44 Billion CNY | 10.8% |
| 2022 Q3 | -8.34 Billion CNY | -78.21% |
| 2022 Q2 | -4.68 Billion CNY | -174.99% |
| 2022 Q1 | 6.24 Billion CNY | 234.02% |
| 2022 FY | -7.44 Billion CNY | -59.76% |
| 2021 Q4 | -4.66 Billion CNY | 0.0% |
| 2021 FY | -4.66 Billion CNY | -66.67% |
| 2021 Q1 | -5.02 Billion CNY | -79.76% |
| 2021 Q2 | -5 Billion CNY | 0.4% |
| 2020 Q4 | -2.79 Billion CNY | 0.24% |
| 2020 Q2 | -3.25 Billion CNY | 0.17% |
| 2020 Q1 | -3.25 Billion CNY | -181.97% |
| 2020 FY | -2.79 Billion CNY | -141.9% |
| 2020 Q3 | -2.8 Billion CNY | 13.86% |
| 2019 Q1 | 1.32 Billion CNY | 256.55% |
| 2019 FY | -1.15 Billion CNY | -36.48% |
| 2019 Q3 | -1.32 Billion CNY | -200.2% |
| 2019 Q2 | 1.32 Billion CNY | 0.0% |
| 2019 Q4 | -1.15 Billion CNY | 13.0% |
| 2018 FY | -846.94 Million CNY | -950.85% |
| 2018 Q4 | -846.94 Million CNY | 0.0% |
| 2017 FY | 99.54 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -8902.717% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 230.54% |